| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
LJP-1586 HCl targets vascular adhesion protein-1 (VAP-1), which is also known as semicarbazide-sensitive amine oxidase (SSAO). VAP-1 is an enzyme involved in the metabolism of primary amines and plays a role in inflammation by mediating leukocyte adhesion and extravasation. By inhibiting VAP-1/SSAO activity, LJP-1586 HCl reduces adhesion molecule expression and immune cell infiltration. The compound inhibits rodent and human SSAO activity with IC50 values in the range of 4 to 43 nM. In vivo, it completely inhibits rat lung SSAO with an ED50 between 0.1 and 1 mg/kg.
|
|---|---|
| ln Vitro |
In vitro, LJP-1586 HCl is a highly selective inhibitor of VAP-1/SSAO activity, with IC50 values in the range of 4 to 43 nM for rodent and human SSAO. Detailed in vitro activity data from specific cell-based assays are not extensively reported. Its high selectivity for VAP-1/SSAO over other amine oxidases contributes to its favorable pharmacological profile.
|
| ln Vivo |
LJP 1586 (0-10 mg/kg, sidewall) can totally block pulmonary SSAO, with an ED50 prevalence time of 0.1 to 1 mg/kg and an effectiveness half-life longer than 24 hours [1].
In vivo, LJP-1586 HCl (0-10 mg/kg, oral) completely inhibits rat lung SSAO with an ED50 between 0.1 and 1 mg/kg, and the pharmacodynamic half-life is greater than 24 hours. It exhibits significant dose-dependent inhibitory activity on neutrophil accumulation. It reduces adhesion molecule expression and immune cell infiltration after intracerebral hemorrhage (ICH), demonstrating anti-inflammatory effects. These in vivo data confirm its oral bioavailability and long duration of action. |
| Enzyme Assay |
Non-cell-based enzyme assays for LJP-1586 HCl use purified SSAO/VAP-1 enzyme or tissue homogenates (e.g., rat lung) containing SSAO activity. The compound is incubated with the enzyme and a substrate (e.g., benzylamine or other primary amines) at varying concentrations. SSAO activity is measured by quantifying the production of hydrogen peroxide or the corresponding aldehyde using spectrophotometric, fluorometric, or radiometric methods. IC50 values for enzyme inhibition are determined from dose-response curves.
|
| Cell Assay |
Cellular assays for LJP-1586 HCl utilize cells expressing VAP-1/SSAO or primary leukocytes to assess inhibition of adhesion and migration. Endothelial cells are treated with the compound, and adhesion molecule expression (e.g., ICAM-1, VCAM-1) is measured by flow cytometry or ELISA. Leukocyte adhesion and transmigration assays are performed using treated endothelial monolayers. Neutrophil accumulation assays may be performed in vitro using chemotaxis chambers.
|
| Animal Protocol |
In vivo animal models for LJP-1586 HCl include models of intracerebral hemorrhage (ICH) to assess anti-inflammatory effects. The compound is administered orally at various doses (0-10 mg/kg). Lung SSAO activity is measured to confirm target engagement. Neutrophil accumulation in tissues is assessed by histological examination or myeloperoxidase assay. Adhesion molecule expression and immune cell infiltration are evaluated by immunohistochemistry or flow cytometry.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of LJP-1586 HCl include a molecular weight of 231.69 g/mol and molecular formula C11H15ClFNO. CAS number is 955037-42-0. The compound is orally bioactive. Purity is >98%. The pharmacodynamic half-life is greater than 24 hours. Detailed PK parameters such as Cmax, Tmax, and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for LJP-1586 HCl are not extensively reported in the available literature. As a research compound, its safety profile would need to be established through standard preclinical toxicity assessments. The compound is supplied for research use only. Given its mechanism of VAP-1 inhibition, potential effects on immune function and amine metabolism would be key safety considerations.
|
| References |
[1]. O'Rourke AM, et al. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther. 2008 Feb;324(2):867-75.
|
| Additional Infomation |
LJP-1586 HCl is also known as LJP-1586 hydrochloride and LJP 1586. It has CAS number 955037-42-0. It is a highly selective inhibitor of vascular adhesion protein-1 (VAP-1)/semicarbazide-sensitive amine oxidase (SSAO). It inhibits rodent and human SSAO activity with IC50 values of 4 to 43 nM. It is orally bioactive. It exhibits anti-inflammatory effects by reducing adhesion molecule expression and immune cell infiltration after ICH. It shows significant dose-dependent inhibition of neutrophil accumulation. Purity is >98%.
|
| Molecular Formula |
C11H15CLFNO
|
|---|---|
| Molecular Weight |
231.69430565834
|
| Exact Mass |
231.082
|
| CAS # |
955037-42-0
|
| Related CAS # |
955037-42-0 (HCl);955041-24-4;
|
| PubChem CID |
46830936
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
186
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.F/C=C(\CN)/CC1C=CC(=CC=1)OC
|
| InChi Key |
GNDHRDJFGYCWER-VEZAGKLZSA-N
|
| InChi Code |
InChI=1S/C11H14FNO.ClH/c1-14-11-4-2-9(3-5-11)6-10(7-12)8-13;/h2-5,7H,6,8,13H2,1H3;1H/b10-7-;
|
| Chemical Name |
(Z)-3-fluoro-2-[(4-methoxyphenyl)methyl]prop-2-en-1-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3161 mL | 21.5806 mL | 43.1611 mL | |
| 5 mM | 0.8632 mL | 4.3161 mL | 8.6322 mL | |
| 10 mM | 0.4316 mL | 2.1581 mL | 4.3161 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
